CompletedNot applicableNCT03893240
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
Studying Glycogen storage disease due to acid maltase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Spark Therapeutics, Inc.
- Principal Investigator
- Tahseen Mozaffar, MDUniversity of California Irvine Health
- Intervention
- Neutralizing Antibody to SPK-3006 capsid(diagnostic_test)
- Enrollment
- 61 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2020
Study locations (18)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- University of California Irvine Health, Orange, California, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Minnesota Medical School, Minneapolis, Minnesota, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Hôpital Raymond-Poincaré, Garches, Hauts-de-Seine, France
- Assistance Publique Hôpitaux de Marseille, Marseille, France
- CHU Nice, Nice, France
- Klinikum der Universität München, München, Germany
- Università degli Studi di Messina, Messina, Italy
- Universita degli Studi di Milano - Clinica Oculistica I, Milan, Italy
- Università degli Studi di Napoli Federico II, Naples, Italy
- Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico, Pavia, Italy
- Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03893240 on ClinicalTrials.govOther trials for Glycogen storage disease due to acid maltase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07478172Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseUniversity of Missouri-Columbia
- RECRUITINGPHASE1, PHASE2NCT07282847A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)AskBio Inc
- RECRUITINGPHASE2NCT07123155Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)Shionogi
- RECRUITINGPHASE4NCT06666413China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDGenzyme, a Sanofi Company
- RECRUITINGNCT06795152Rare Glycogen Storage Diseases Natural History StudyDuke University
- RECRUITINGPHASE1, PHASE2NCT06391736Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy DrugGeneCradle Inc
- RECRUITINGNCT06121011A Global Prospective Observational Registry of Patients With Pompe DiseaseAmicus Therapeutics
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06109948Study to Assess the Safety, Tolerability, PK and PD of ABX1100Aro Biotherapeutics
See all trials for Glycogen storage disease due to acid maltase deficiency →